Kissei Pharmaceutical Co., Ltd. (TYO:4547)
4,085.00
+15.00 (0.37%)
Aug 25, 2026, 3:24 PM JST
Kissei Pharmaceutical Revenue
Kissei Pharmaceutical had revenue of 23.39B JPY in the quarter ending June 30, 2026, with 5.40% growth. This brings the company's revenue in the last twelve months to 98.60B, up 10.35% year-over-year. In the fiscal year ending March 31, 2026, Kissei Pharmaceutical had annual revenue of 97.41B with 10.28% growth.
Revenue (ttm)
98.60B
Revenue Growth
+10.35%
P/S Ratio
1.71
Revenue / Employee
55.21M
Employees
1,786
Market Cap
168.71B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 97.41B | 9.08B | 10.28% |
| Mar 31, 2025 | 88.33B | 12.75B | 16.87% |
| Mar 31, 2024 | 75.58B | 8.09B | 11.98% |
| Mar 31, 2023 | 67.49B | 2.11B | 3.23% |
| Mar 31, 2022 | 65.38B | -3.66B | -5.31% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sumitomo Pharma | 474.79B |
| Towa Pharmaceutical | 279.94B |
| Sawai Group Holdings | 203.79B |
| Tsumura & Co. | 199.23B |
| Nippon Shinyaku | 180.29B |
| KYORIN Pharmaceutical | 125.68B |
| Mochida Pharmaceutical | 122.04B |
| Zeria Pharmaceutical | 91.12B |
Kissei Pharmaceutical News
- 25 days ago - Kissei Pharmaceutical Quarterly report: Q1 2027 - Filings
- 25 days ago - Kissei Pharmaceutical Slides: Q1 2027 - Filings
- 3 months ago - Kissei Pharmaceutical Quarterly report: Q4 2026 - Filings
- 3 months ago - Kissei Pharmaceutical Slides: Q4 2026 - Filings
- 7 months ago - Kissei Pharmaceutical Quarterly report: Q3 2026 - Filings
- 9 months ago - Kissei Pharmaceutical initiated with a Neutral at UBS - TheFly
- 10 months ago - Kissei Pharmaceutical Quarterly report: Q2 2026 - Filings
- 10 months ago - Kissei Pharmaceutical Slides: Q2 2026 - Filings